List of Excipients in Branded Drug EPIPEN JR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dispensing Solutions Inc	EPIPEN JR	epinephrine	55045-3598	HYDROCHLORIC ACID
Dispensing Solutions Inc	EPIPEN JR	epinephrine	55045-3598	NITROGEN
Dispensing Solutions Inc	EPIPEN JR	epinephrine	55045-3598	SODIUM CHLORIDE
Dispensing Solutions Inc	EPIPEN JR	epinephrine	55045-3598	SODIUM METABISULFITE
Dispensing Solutions Inc	EPIPEN JR	epinephrine	55045-3598	WATER

Last updated: August 2, 2026

Executive summary: EpiPen Jr’s excipient strategy is conservative and stability-driven. The product uses a simple aqueous epinephrine formulation containing sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection. The commercial moat is the integrated drug-device system, emergency-use brand recognition, pharmacy distribution, and user familiarity rather than a complex excipient platform. Opportunities exist in sulfite-free or reduced-sulfite formulations, longer shelf life, pediatric 0.1 mg presentations, lower-cost device components, and alternative delivery systems. Generic competition has reduced formulation exclusivity, while device usability and supply reliability remain the main commercial differentiators.

EpiPen Jr Excipient Strategy, Patent Position, and Commercial Opportunities

What is EpiPen Jr and what excipients does it contain?

EpiPen Jr is a single-dose epinephrine auto-injector delivering 0.15 mg of epinephrine for emergency treatment of anaphylaxis. The labeled weight range is approximately 15 kg to 30 kg, or 33 lb to 66 lb, although clinicians determine use based on the patient’s clinical circumstances [1].

The EpiPen Jr solution contains:

Component	Function
Epinephrine	Active pharmaceutical ingredient
Sodium chloride	Tonicity adjustment
Sodium metabisulfite	Antioxidant and stability agent
Hydrochloric acid	pH adjustment
Water for injection	Vehicle

The formulation is a sterile aqueous solution in a prefilled cartridge connected to an automatic injection mechanism. The product is designed for rapid intramuscular delivery through clothing when necessary. The labeled dose is 0.15 mg in 0.15 mL, equivalent to 1 mg/mL epinephrine concentration [1].

EpiPen Jr does not use a complex controlled-release excipient system. Its formulation strategy prioritizes:

1. Protection of epinephrine against oxidation.
2. Chemical stability during labeled storage.
3. Low viscosity for rapid injection.
4. Compatibility with the cartridge, syringe, needle, and injector mechanism.
5. Manufacturability at high volume.

Why does EpiPen Jr use sodium metabisulfite?

Sodium metabisulfite is included to limit oxidative degradation of epinephrine. Epinephrine is chemically sensitive to oxidation, light, oxygen exposure, pH conditions, and trace metal contamination. Oxidative degradation can produce colored and inactive degradation products, including adrenochrome-related species.

The product label warns that EpiPen Jr contains a sulfite. Sulfites can cause allergic-type reactions, including anaphylactic symptoms, in susceptible patients. The FDA label states that the presence of a sulfite should not prevent use in a life-threatening allergic emergency because the therapeutic benefit outweighs the sulfite-related risk in that setting [1].

This creates a formulation tradeoff:

Formulation objective	Benefit	Commercial constraint
Retain sodium metabisulfite	Established stability profile and manufacturing process	Sulfite warning and potential patient concern
Reduce sulfite concentration	May improve labeling position	Requires new stability, container, and process evidence
Remove sulfite	Differentiated product positioning	Higher oxidation risk and potentially greater development cost
Use another antioxidant	May avoid sulfite exposure	New compatibility, toxicology, and regulatory package

A sulfite-free EpiPen Jr would not be a simple excipient substitution. The sponsor would need to demonstrate stability across the full shelf life, including oxygen exposure, light stress, temperature excursions, device aging, and dose delivery after storage.

What excipient opportunities exist for a next-generation EpiPen Jr?

Sulfite-free epinephrine formulations

The most visible opportunity is a sulfite-free or low-sulfite epinephrine injection. A successful product could target parents and clinicians concerned about sulfite exposure, even though current labeling supports EpiPen Jr use during life-threatening emergencies.

A sulfite-free formulation would require control of multiple degradation pathways. Potential strategies include:

• Improved oxygen-barrier cartridge materials.
• Reduced headspace oxygen.
• Nitrogen purging during filling.
• Tighter control of trace metals.
• Alternative antioxidants.
• Optimized pH.
• Light-protective packaging.
• Lower-permeability seals and plungers.
• Manufacturing under controlled oxygen conditions.

The commercial value would depend on whether the product can achieve a clinically meaningful shelf-life advantage or a clear labeling benefit. A sulfite-free claim alone may not support premium pricing if the injector remains difficult to use or supply is unreliable.

Improved container-closure systems

The cartridge and closure system are as important as the liquid formulation. Epinephrine degradation can result from oxygen ingress, extractables, leachables, adsorption, and interaction with elastomeric components.

Potential improvements include:

• Cyclic olefin polymer or other high-barrier materials.
• Low-extractable elastomer components.
• Reduced oxygen permeability.
• Better protection from ultraviolet and visible light.
• More consistent dose delivery after long-term storage.
• Smaller internal dead volume.

These changes may support a new drug-device combination or supplemental approval, depending on the extent of formulation and container changes.

Longer shelf life and better temperature tolerance

EpiPen Jr is stored at controlled room temperature and should be protected from extreme heat, cold, and light. A product with a longer shelf life or greater resistance to temperature excursions could reduce replacement waste in schools, pharmacies, families, airlines, and emergency departments.

The commercial opportunity is material because epinephrine auto-injectors are often purchased for emergency readiness and may expire without use. A longer dating period could lower total ownership cost and improve stocking economics.

Pediatric 0.1 mg presentation

EpiPen Jr delivers 0.15 mg and is generally labeled for patients weighing 15 kg to 30 kg. Some younger or smaller children may receive a dose that is high relative to weight. A 0.1 mg epinephrine auto-injector could address the gap between infant dosing and the current 0.15 mg product.

A lower-dose device would require:

• A new dose strength.
• A new delivery-volume specification.
• Pediatric needle-depth and injection-force assessment.
• Human-factors testing involving caregivers.
• Updated labeling and dosing guidance.
• Manufacturing segregation to prevent strength mix-ups.

The 0.1 mg segment is a device and dosing opportunity more than an excipient opportunity. The same core formulation may be usable at a different fill volume, but the sponsor would need to establish dose uniformity, stability, and delivery performance.

How does EpiPen Jr compare with competing epinephrine products?

Product	Dose relevant to pediatric use	Delivery format	Formulation or device distinction
EpiPen Jr	0.15 mg	Auto-injector	Established epinephrine solution with sulfite antioxidant
Generic epinephrine auto-injectors	0.15 mg and other strengths	Auto-injector	Generally comparable drug product and delivery function
Auvi-Q	0.1 mg, 0.15 mg, 0.3 mg	Voice-guided auto-injector	Electronic instructions and compact device design
Manual epinephrine syringe	Variable	Manual injection	Lower device cost but greater administration burden
Intranasal epinephrine candidates	Potentially variable	Nasal delivery	Could eliminate needle use if approved and clinically adequate

Auvi-Q has competed through compact design, voice instructions, and a 0.1 mg pediatric option. Generic EpiPen products compete primarily on price and pharmacy access. A future intranasal epinephrine product could compete on needle avoidance, but it would need to demonstrate reliable systemic exposure during anaphylaxis.

What patents protect EpiPen Jr and how strong is the patent estate?

EpiPen Jr is a small-molecule drug-device combination. Its historical protection has centered more on injector mechanics, cartridge integration, dose delivery, safety mechanisms, and user interface than on novel excipients.

The key patent categories are:

Patent category	Relevance to EpiPen Jr
Epinephrine composition patents	Limited, because epinephrine is an established active ingredient
Excipient patents	Possible protection for sulfite-free or stabilized formulations
Container-closure patents	Protection for cartridge, seal, oxygen control, and compatibility
Auto-injector patents	Protection for activation, needle deployment, dose delivery, and safety
Human-factors patents	Protection for instructions, sound or voice guidance, and user interface
Manufacturing patents	Protection for filling, oxygen control, assembly, and quality testing

The traditional EpiPen patent moat has weakened as key device and product protections expired or became vulnerable to design-around strategies. Generic epinephrine auto-injectors have entered the U.S. market, including Teva’s generic EpiPen products, which received FDA approval in 2018 [2].

The remaining barriers are practical rather than purely legal:

• FDA combination-product requirements.
• Device reliability and dose accuracy.
• Human-factors validation.
• Cartridge and needle supply.
• Manufacturing scale.
• Pharmacy substitution and reimbursement access.
• Product liability exposure.
• School and institutional purchasing contracts.

A sponsor developing a new epinephrine auto-injector should conduct a current freedom-to-operate analysis covering active U.S. and foreign patents. Patent risk may be concentrated in device architecture and manufacturing rather than in the base epinephrine solution.

What is the FDA regulatory status of EpiPen Jr?

EpiPen Jr is an FDA-approved prescription epinephrine auto-injector marketed under the EpiPen brand. It is regulated as a drug-device combination product because the drug solution and injector mechanism function together [1].

The FDA regulatory record includes several commercially relevant milestones:

Milestone	Date or status
EpiPen brand development and commercialization	Longstanding U.S. market presence
EpiPen Jr approval	Original approval predates current generic competition
Generic EpiPen approval	Teva approval announced in 2018
Authorized and branded generic availability	Commercially present in the U.S. market
FDA Orange Book relevance	Drug patents and exclusivity must be assessed against the current listing

EpiPen Jr is not a biologic, so biosimilar rules do not apply. Competition occurs through abbreviated new drug applications, authorized generics, branded competitors, and new drug-device products.

When does EpiPen Jr lose exclusivity?

EpiPen Jr no longer has meaningful market exclusivity based solely on the original epinephrine formulation. Generic competition is already established. The relevant commercial question is not the first loss of exclusivity, but the durability of the brand’s residual share.

Residual advantages may include:

• Brand recognition among caregivers.
• Prescriber familiarity.
• School and emergency protocol standardization.
• Availability through major pharmacy networks.
• Device training materials.
• Contracting and reimbursement arrangements.
• Consumer preference for a familiar injector.

The Orange Book may contain product-specific patent and exclusivity information, but the existence of an Orange Book listing does not by itself establish a durable barrier to a competing design. Paragraph IV challenges can target listed patents, while a non-infringing product may proceed through a different device architecture.

Which companies are challenging EpiPen Jr commercially?

The competitive field includes:

• Viatris and its EpiPen brand.
• Teva and other generic epinephrine auto-injector suppliers.
• Kaleo, which markets Auvi-Q.
• Potential developers of lower-dose pediatric or needle-free epinephrine products.
• Private-label and authorized-generic channels.

The most important competitive distinction is not excipient complexity. It is the combination of dose accuracy, activation reliability, ease of use, price, availability, and payer coverage.

What paragraph IV, litigation, and settlement risks affect EpiPen Jr?

EpiPen-related patent disputes have historically focused on injector design, manufacturing, and generic product entry. Generic applicants may use Paragraph IV certifications to challenge listed patents or certify that their products do not infringe.

The major legal risks for a new entrant are:

1. Patent infringement claims involving the injector mechanism.
2. Trade dress and brand-confusion claims.
3. Device equivalence disputes.
4. Product liability claims involving failure to activate or improper injection.
5. Antitrust and contracting scrutiny involving branded and authorized-generic supply.
6. Exclusivity disputes involving FDA approval timing.

No biosimilar litigation framework applies. Settlement agreements can affect generic launch dates, supply rights, and authorized-generic competition, but the economic terms of individual agreements are not always public.

What commercial opportunities exist for excipient suppliers?

Excipient and component suppliers can pursue several opportunities around EpiPen Jr-type products.

High-barrier packaging

Suppliers of oxygen-resistant cartridges, seals, plungers, and light-protective systems can support longer shelf life and sulfite reduction. The highest value lies in components that improve stability without changing injector performance.

Alternative antioxidant systems

A supplier with a well-characterized antioxidant or oxygen-control technology could license a formulation platform to an epinephrine developer. The value proposition must include toxicology, extractables and leachables data, and a regulatory path.

Low-temperature and heat-stable systems

School stockpiles, ambulances, aircraft, and international distribution create demand for products that tolerate temperature excursions. A formulation or container system that improves stability under stress testing could support institutional contracts.

Contract manufacturing

Commercial opportunities exist in:

• Sterile epinephrine filling.
• Cartridge assembly.
• Auto-injector assembly.
• Device testing.
• Combination-product packaging.
• Serialization and global distribution.

Manufacturing barriers are significant because the product requires reliable sterile filling and precise mechanical assembly. A formulation improvement that cannot be scaled into a consistent device product has limited commercial value.

How much revenue exposure does EpiPen Jr represent?

Public company disclosures generally report EpiPen sales at the brand or epinephrine auto-injector level rather than isolating EpiPen Jr revenue. The commercial exposure includes both direct sales and broader portfolio effects:

• Pediatric prescriptions.
• Two-pack replacement purchases.
• School and institutional stocking.
• Emergency department discharge programs.
• International sales.
• Generic price erosion.
• Brand-to-generic substitution.

The pediatric segment is strategically important because caregivers often seek a product with a clear dose, simple instructions, and strong availability. A lower-cost generic can capture volume, while a differentiated product can preserve pricing through device usability or formulation claims.

Key Takeaways

• EpiPen Jr uses a simple aqueous epinephrine formulation with sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection.
• Sodium metabisulfite is primarily a stability excipient that limits epinephrine oxidation.
• The strongest formulation opportunity is a sulfite-free or reduced-sulfite product with equal or better shelf life.
• High-barrier cartridges, improved seals, lower oxygen exposure, and better temperature tolerance may support new product differentiation.
• A 0.1 mg pediatric auto-injector is a major unmet product-positioning opportunity.
• EpiPen Jr has no biosimilar pathway because epinephrine is a small molecule.
• Generic competition is established, including Teva’s FDA-approved generic EpiPen product.
• Remaining competitive barriers are concentrated in device reliability, human factors, supply, reimbursement, and manufacturing quality.
• The original formulation provides limited exclusivity. New protection would likely depend on formulation, container-closure, device, or manufacturing claims.
• Commercial value is tied to emergency readiness, brand trust, pharmacy access, and institutional purchasing rather than excipient complexity alone.

FAQs about EpiPen Jr excipients and commercial strategy

Does EpiPen Jr contain preservatives?

EpiPen Jr contains sodium metabisulfite, which functions as an antioxidant and produces the product’s sulfite warning. It is not used as a conventional antimicrobial preservative.

Could a sulfite-free EpiPen Jr be approved?

Yes. A sulfite-free epinephrine auto-injector could be developed through an appropriate FDA application, but the sponsor would need to establish chemical stability, container compatibility, sterility, dose accuracy, and device performance.

Is sodium metabisulfite in EpiPen Jr the same as sulfite in food?

Both relate to sulfite chemistry, but exposure, concentration, route of administration, and clinical context differ. The EpiPen Jr label specifically warns about sulfite sensitivity and directs that the product still be used for life-threatening anaphylaxis [1].

Does EpiPen Jr have patent protection on its excipients?

The base excipient combination is unlikely to provide a strong standalone barrier because sodium chloride, sodium metabisulfite, hydrochloric acid, and water are established pharmaceutical materials. Patent value would more likely arise from a new stabilized formulation, container system, or device configuration.

What is the strongest commercial alternative to EpiPen Jr?

Auvi-Q is the principal branded alternative in the U.S. pediatric segment because it offers a compact device, voice-guided instructions, and a 0.1 mg strength. Generic epinephrine auto-injectors are the main price competitors.

References

1. U.S. Food and Drug Administration. (2023). EpiPen and EpiPen Jr prescribing information. FDA.
2. Teva Pharmaceuticals. (2018, August 16). Teva announces U.S. launch of generic EpiPen auto-injector. Teva Pharmaceuticals.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
4. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.
5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.